文献速递骨软组织肉瘤与黑色素瘤

MAPK抑制剂诱导黑色素瘤消退及早期适应中的复发肿瘤细胞内在与外在改变

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
PubMed 文献 · Cancer Discov · 2017-09-01

该研究比较了MAPK抑制剂(MAPKi)治疗后退缩中的患者来源肿瘤转录组与人类黑色素瘤细胞系或免疫健全小鼠黑色素瘤中MAPKi诱导的时序转录组状态。尽管临床肿瘤退缩动态异质,残留肿瘤显示高度复发的转录组改变和富集过程,这些改变也见于MAPKi选择的细胞系(提示肿瘤细胞内在重编程)或bulk小鼠肿瘤(及CD45阴性或阳性组分,分别提示肿瘤细胞内在或基质/免疫改变)。肿瘤细胞内在重编程减弱MAPK依赖性,同时增强间质、血管生成和IFN炎症特征以及对多RTK和PD-L2的生长/生存依赖。免疫区室中CD11c+免疫细胞PD-L2上调驱动T细胞炎症丢失并促进BRAFi耐药。

要点

  • 残留黑色素瘤在MAPKi治疗早期已显示潜在的适应性转录组、表观基因组、免疫调控组改变。
  • 肿瘤细胞内在重编程减弱MAPK依赖性,增强间质、血管生成和IFN炎症特征。
  • CD11c+免疫细胞PD-L2上调驱动T细胞炎症丢失并促进BRAFi耐药。

核心结论

  • MAPKi诱导的黑色素瘤不完全退缩导致转录组/甲基化组广泛重编程和MAPK冗余逃逸。

研究设计与样本

  • 比较患者来源肿瘤在MAPKi治疗后退缩中的转录组与人类黑色素瘤细胞系或免疫健全小鼠黑色素瘤中MAPKi诱导的时序转录组状态。

主要发现

  • 残留肿瘤显示高度复发的转录组改变和富集过程,也见于MAPKi选择的细胞系或bulk小鼠肿瘤及CD45阴性或阳性组分。
  • 肿瘤细胞内在重编程减弱MAPK依赖性,增强间质、血管生成和IFN炎症特征及对多RTK和PD-L2的生长/生存依赖。
  • CD11c+免疫细胞PD-L2上调驱动T细胞炎症丢失并促进BRAFi耐药。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of advanced BRAFV600-mutant melanoma using a BRAF inhibitor or its combination with a MEK inhibitor typically elicits partial responses. We compared the transcriptomes of patient-derived tumors regressing on MAPK inhibitor (MAPKi) therapy against MAPKi-induced temporal transcriptomic states in human melanoma cell lines or murine melanoma in immune-competent mice. Despite heterogeneous dynamics of clinical tumor regression, residual tumors displayed highly recurrent transcriptomic alterations and enriched processes, which were also observed in MAPKi-selected cell lines (implying tumor cell-intrinsic reprogramming) or in bulk mouse tumors (and the CD45-negative or CD45-positive fractions, implying tumor cell-intrinsic or stromal/immune alterations, respectively). Tumor cell-intrinsic reprogramming attenuated MAPK dependency, while enhancing mesenchymal, angiogenic, and IFN-inflammatory features and growth/survival dependence on multi-RTKs and PD-L2. In the immune compartment, PD-L2 upregulation in CD11c+ immunocytes drove the loss of T-cell inflammation and promoted BRAFi resistance. Thus, residual melanoma early on MAPKi therapy already displays potentially exploitable adaptive transcriptomic, epigenomic, immune-regulomic alterations.Significance: Incomplete MAPKi-induced melanoma regression results in transcriptome/methylome-wide reprogramming and MAPK-redundant escape. Although regressing/residual melanoma is highly T cell-inflamed, stromal adaptations, many of which are tumor cell-driven, could suppress/eliminate intratumoral T cells, reversing tumor regression. This catalog of recurrent alterations helps identify adaptations such as PD-L2 operative tumor cell intrinsically and/or extrinsically early on therapy. Cancer Discov; 7(11); 1248-65. ©2017 AACR.See related commentary by Haq, p. 1216This article is highlighted in the In This Issue feature, p. 1201.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Song C, Piva M, Sun L, et al. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov. 2017. PMID: 28864476. doi:10.1158/2159-8290.CD-17-0401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。